Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Other Accumulated Expenses (2018 - 2025)

Historic Other Accumulated Expenses for Tg Therapeutics (TGTX) over the last 8 years, with Q3 2025 value amounting to $2.0 million.

  • Tg Therapeutics' Other Accumulated Expenses fell 3956.94% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 million, marking a year-over-year decrease of 3956.94%. This contributed to the annual value of $4.6 million for FY2024, which is 21284.65% up from last year.
  • Tg Therapeutics' Other Accumulated Expenses amounted to $2.0 million in Q3 2025, which was down 3956.94% from $2.3 million recorded in Q2 2025.
  • In the past 5 years, Tg Therapeutics' Other Accumulated Expenses ranged from a high of $14.5 million in Q1 2021 and a low of $807000.0 during Q3 2022
  • In the last 5 years, Tg Therapeutics' Other Accumulated Expenses had a median value of $2.0 million in 2025 and averaged $4.1 million.
  • Per our database at Business Quant, Tg Therapeutics' Other Accumulated Expenses tumbled by 9360.94% in 2022 and then surged by 23284.19% in 2024.
  • Quarter analysis of 5 years shows Tg Therapeutics' Other Accumulated Expenses stood at $1.5 million in 2021, then decreased by 22.69% to $1.2 million in 2022, then grew by 26.52% to $1.5 million in 2023, then surged by 212.85% to $4.6 million in 2024, then tumbled by 56.93% to $2.0 million in 2025.
  • Its Other Accumulated Expenses stands at $2.0 million for Q3 2025, versus $2.3 million for Q2 2025 and $2.9 million for Q1 2025.